Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Theranostic Imaging and Dosimetry for Cancer
share announcement

Theranostic Imaging and Dosimetry for Cancer

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Methods and Technologies Development".

Deadline for manuscript submissions: 1 June 2024 | Viewed by 1610

Special Issue Editors

Dr. Christian Happel

E-Mail Website
Guest Editor
Department of Nuclear Medicine, University Hospital, Goethe University, Frankfurt, Germany
Interests: 177Lu-radioligand therapy; radioiodine-131 therapy; PET/CT; molecular imaging
Dr. Daniel Groener

E-Mail Website
Guest Editor
Department of Nuclear Medicine, University Hospital, Goethe University, Frankfurt, Germany
Interests: theragnostic; thyroid cancer; PET/CT; radioligand therapy; radioembolization

Special Issue Information

Dear Colleagues,

It is our privilege to invite you to contribute to this Special Issue highlighting the role of theranostic imaging and dosimetry in oncologic treatments.

Today, a targeted approach in oncologic therapies seems hardly imaginable without the use of modern structural and molecular imaging modalities. The anatomically guided perspective of radiological diagnostics (CT and MRI) is broadened by the functional insight of nuclear medicine (SPECT and PET). These distinct perspectives may add up concordantly or be of complementary value in hybrid imaging (SPECT/CT, PET/CT, PET/MRI). Quantitative hybrid imaging is also a key to implementing dosimetric calculation in patients receiving radionuclide therapies, thus allowing for better patient selection, radiation safety, and personalized treatment approaches. An active dialog within the interrelated fields of radiology, nuclear medicine, and radiation therapy including experts in radiation physics is essential to further implement the emerging concept of "theranostics" and to optimize oncologic outcomes in treated patients.

Therefore, the aim of this Special Issue is to pinpoint and discuss newly established and recent approaches in radiology and nuclear medicine as well as associated fields of clinical and experimental research to refine cancer diagnostics, molecular therapies, and individualized dosimetry.

In this Special Issue, original research articles and reviews are welcome. We look forward to receiving your contributions.

Dr. Christian Happel
Dr. Daniel Groener
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • PET/CT
  • SPECT/CT
  • dosimetry
  • radionuclide therapy
  • radioembolization
  • radioligand therapy
  • nuclear medicine

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

14 pages, 4210 KiB  
Article
Transarterial Radioembolization Planning and Treatment with Microspheres Containing Holmium-166: Determination of Renal and Intestinal Radionuclide Elimination, Effective Half-Life, and Regulatory Aspects
by Christian Kühnel, Falk Gühne, Philipp Seifert, Robert Freudenberg, Martin Freesmeyer and Robert Drescher
Cancers 2023, 15(1), 68; https://doi.org/10.3390/cancers15010068 - 22 Dec 2022
Viewed by 1437
Abstract
After transarterial radioembolization (TARE) with microspheres loaded with holmium-166, radioactivity is excreted from the body. The aim of this study was to evaluate radioactive renal and intestinal excretions after TARE planning and treatment procedures with holmium-166-loaded microspheres and to correlate the findings with [...] Read more.
After transarterial radioembolization (TARE) with microspheres loaded with holmium-166, radioactivity is excreted from the body. The aim of this study was to evaluate radioactive renal and intestinal excretions after TARE planning and treatment procedures with holmium-166-loaded microspheres and to correlate the findings with the intratherapeutic effective half-life. Urinary and intestinal excretions of patients who underwent TARE procedures were collected during postinterventional intervals of 24 h (TARE planning) and 48 h (TARE treatment). Whole-body effective half-life measurements were performed. Calibrations of the 166Ho measuring system showed evidence of long-living nuclides. For excretion determination, 22 TARE planning procedures and 29 TARE treatment procedures were evaluated. Mean/maximum total excretion proportions of the injected 166Ho were 0.0038%/0.0096% for TARE planning procedures and 0.0061%/0.0184% for TARE treatment procedures. The mean renal fractions of all measured excretions were 97.1% and 98.1%, respectively. Weak correlations were apparent between the injected and excreted activities (R2 planning/treatment: 0.11/0.32). Mean effective 166Ho half-lives of 24.03 h (planning) and 25.62 h (treatment) confirmed low excretions. Radioactive waste disposal regulations of selected jurisdictions can be met but must be reviewed before implementing this method into clinical practice. Inherent long-living nuclide impurities should be considered. Full article
(This article belongs to the Special Issue Theranostic Imaging and Dosimetry for Cancer)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop